Doc.RNDr. Šárka Pospíšilová, Ph.D.
Pracoviště: LF MU a FN Brno, IHOK a CEITEC (Jihlavská 20, 625 00 Brno)
E-mail: sarka.pospisilova@fnbrno.cz
Odborné práce publikované na Linkos.cz
Níže se zobrazuje autorství některých typů informací, které jsou součástí databazí na Linkos a také autorství článků pro pacienty na Linkos. Vypisují se knihy, články v Klinické onkologii a onkologické péči, tuzemská abstrakta zažazená do databáze abstrakt, brožury pro pacienty a také texty pro pacienty na Linkos. Rejstřík v žádném případě není úplným autorským rejstříkem, protože nejpodstatnější publikace a sice publikace v zahraničních časopisech tento způsob nezobrazuje.
Publikovaná abstrakta
- ANALYSIS OF POTENTIALLY BICLONAL CLL PATIENTS WITH TWO OR THREE PRODUCTIVE IGH REARRANGEMENTS
- Analýza genové exprese u folikulárního lymfomu pomocí oligonukleotidových microarrays
- CLL-SPECIFIC RESEQUENCING MICROARRAY AS A TOOL FOR CLL RESEARCH AND DIAGNOSTICS
- Clonal Evolution of Malignant Populations In Potentially Biclonal Chronic Lymphocytic Leukemia Patients
- DEFINITION AND VALIDATION OF NOVEL PROGNOSTIC MARKERS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
- Detail Characterization of 22q11 Deletion and Mir-650 Role in CLL Patients
- DNA čipy (microarrays) a jejich využití v onkologické diagnostice
- EVALUATION OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING RESEQUENCING MICROARRAY PLATFORMS
- FOCUSED MICROARRAY FOR LYMPHOMA DIAGNOSTICS
- Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease
- Gene-Expression Profiling of Graft-Versus-Host Disease by Oligonucleotide Microarrays
- Human Embryonic Stem Cells: Stable or Vulnerable?
- CHARACTERIZATION OF 22Q11 DELETION IN CLL PATIENTS
- CHARACTERIZATION OF P53 AND ATM ABNORMALITIES IN B-CLL PATIENTS
- CHLORAMBUCIL (CHL) AND FLUDARABINE (F) AS A NEW PRE-TRANSPLANT CONDITIONING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF IN VITRO AND IN VIVO EXPERIMENTS
- Chronic Lymphocytic Leukemia with Stereotyped IGHV4-59/IGKV3-20 B Cell Receptors: Another Manifestation of Hepatitis C Virus-Associated B Cell Lymphoproliferation?
- Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target
- MICRORNA-34A IS SIGNIFICANTLY DOWN-REGULATED IN B-CLL PATIENTS WITH P53 ABNORMALITIES
- MICRORNAS EXPRESSION PATTERN IN AGGRESSIVE SUBTYPE OF CHRONIC LYMPHOCYTIC LEUKEMIA
- MISSENSE MUTATIONS LOCATED IN STRUCTURAL P53 DNA-BINDING MOTIFS ARE ASSOCIATED WITH EXTREMELY POOR SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Molekulárně-biologické přístupy mutační analýzy genu TP53 u onkologických pacientů.
- MONITORING OF MINIMAL RESIDUAL DISEASE IN MANTLE CELL LYMPHOMA
- MONITORING OF THE STATUS OF BOTH P53 ALLELES IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RELEVANCE TO PROGNOSIS AND TREATMENT
- Mutational Analysis of Mir-29 Family Members in Chronic Lymphocytic Leukemia
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- NOD/SCID IL2RGAMMA(-/-) XENOGRAFT MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA
- NON-HODGKIN LYMPHOMA SUBTYPES CLASSIFICATION USING FOCUSED MICROARRAY
- P53 Inactivation and Genomic Aberrations in Relation to Imatinib Resistance in Chronic Myeloid Leukemia
- PCR DETECTION OF NON-MTC T(11;14) TRANSLOCATIONS IN MANTLE CELL LYMPHOMA
- PRESENCE OF HETEROZYGOUS ATM DELETION MAY NOT BE CRITICAL FOR THE RESPONSE OF CLL CELLS TO FLUDARABINE
- PROGNOSIS OF RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER COMBINED FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) TREATMENT
- Prognostický význam mutačního stavu genu TP53 u pacientů s B-buněčnou chronickou lymfocytární leukémií – význam monitorováni obou alel.
- Přítomnost heterozygotní delece ATM nedeterminuje odpověď CLL buněk na fludarabin
- REARRANGEMENT OF LAMBDA IMMUNOGLOBULIN LIGHT CHAIN IN CLL IS COUPLED WITH MIRNA-650 EXPRESSION
- RELATIONSHIP BETWEEN THERAPY AND CLONAL EVOLUTION OF TP53 ABNORMALITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Rituximab Sensitizes B-CLL Cells with Inactivated p53 to Fludarabine.
- RITUXIMAB SENSITIZES SOME B-CLL SAMPLES TO FLUDARABINE AND CHLORAMBUCIL IN VITRO, REGARDLESS OF P53/ATM STATUS
- Role of p53 Gene Mutation Type in B-CLL Prognosis
- SENSITIZATION OF LEUKEMIC CELLS TO FLUDARABINE BY MONOCLONAL ANTIBODY RITUXIMAB - IDENTIFICATION OF RESPONSIBLE GENES
- Sledování exprese vybraných genů u pacientů s B-buněčnou chronickou lymfocytární leukémií – záchyt změny leukemického klonu vlivem terapie
- T(14;18) IN FOLLICULAR LYMPHOMA: A REAL- TIME (PCR) FOR A REAL LIFE….?
- THE IMPACT OF SPECIFIC MUTATIONS IN TP53 GENE ON THE RESULTS OF ALEMTUZUMAB THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?
- The Regulation, Targets and Clinical Relevance of Microrna Mir-650 in Chronic Lymphocytic Leukemia (CLL)
- TRANSLOCATION IS A FREQUENT MECHANISM FOR 17P DELETION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Využití DNA microarrays v diagnostice lymfocytárních leukémií.
- Využití long-oligonucleotide arrayCGH v diagnostice leukémií.
- Využití RNA interference při regulaci genové exprese antionkogenu p53
- Využití RNA interference při regulaci genové exprese antionkogenu p53
- WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?
- WHAT DO WE KNOW ABOUT THE REAL INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND WHERE AND HOW ARE THE PATIENTS WITH CLL TREATED?